Aroa Biosurgery (ASX:ARX) is a New Zealand-based medical-technology company that develops soft-tissue regeneration products from a proprietary ovine (sheep) tissue platform, used in surgical and wound-care applications, with its main market in the United States. Its products — including its Symphony and Enivo lines — address large surgical markets, and the company has been scaling toward sustained profitability.

For FY26, Aroa reported Revenue of around NZ$104 million, up 23%, and a second consecutive year of positive EBITDA, with normalised EBITDA tripling, exceeding its FY26 guidance. The company set ambitious FY27 targets and emphasised its United States growth strategy, including the Symphony and Enivo product lines.

What Could Drive the Shares Next?

Catalysts include continued United States revenue growth, uptake of the Symphony and Enivo product lines, delivery of the ambitious FY27 targets, and further improvement in profitability. Evidence that the Business can keep compounding revenue and EBITDA would support the case.

Sustained growth toward the FY27 targets would be the clearest signal that the market is underestimating the story.

Risks Investors Should Watch

Aroa is exposed to the pace of adoption of its products in the competitive United States surgical market and to reimbursement dynamics. Growth expectations, reflected in the FY27 targets, are a consideration if progress slows.

Competition, execution on new product lines, and currency movements given its New Zealand base are additional factors.

Investor Takeaway

Aroa Biosurgery grew FY26 revenue 23% to around NZ$104 million with normalised EBITDA tripling and a second year of positive EBITDA, ahead of guidance. Whether the market is underestimating the story depends on United States growth and delivering its FY27 targets. Revenue growth, product uptake and profitability are the things to watch.